Pathophysiology-directed therapy for acute hypoxemic respiratory failure in acute myeloid leukemia with hyperleukocytosis

Jeffrey E. Schmidt, Robert Tamburro, Elaine M. Sillos, D. Ashley Hill, Raul C. Ribeiro, Bassem I. Razzouk

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

A 17-year-old with acute myeloid leukemia M4 and hyperleukocytosis developed fulminant hypoxemic respiratory failure at presentation. After failing to respond to conventional mechanical ventilation and leukapheresis, he was started on inhaled nitric oxide (iNO) with dramatic improvement in oxygenation. Following graduated chemotherapy, his pulmonary status again deteriorated coincident with tumor lysis. After failing to respond to increases in iNO, he was placed in prone position with immediate improvement. The patient was successfully extubated. Patients with myelomonocytic leukemias are at risk for early death due to pulmonary complications. The use of adjuvant therapies directed by specific pathophysiology might decrease this risk.

Original languageEnglish (US)
Pages (from-to)569-571
Number of pages3
JournalJournal of Pediatric Hematology/Oncology
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2003

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Pathophysiology-directed therapy for acute hypoxemic respiratory failure in acute myeloid leukemia with hyperleukocytosis'. Together they form a unique fingerprint.

  • Cite this